Growth Metrics

Coherus Oncology (CHRS) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $372.3 million.

  • Coherus Oncology's Total Current Liabilities rose 2596.07% to $372.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.3 million, marking a year-over-year increase of 2596.07%. This contributed to the annual value of $283.0 million for FY2024, which is 1470.59% down from last year.
  • Per Coherus Oncology's latest filing, its Total Current Liabilities stood at $372.3 million for Q3 2025, which was up 2596.07% from $263.6 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Total Current Liabilities registered a high of $538.3 million during Q1 2024, and its lowest value of $123.4 million during Q1 2023.
  • Its 5-year average for Total Current Liabilities is $261.6 million, with a median of $257.6 million in 2021.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 33620.14% in 2024, then crashed by 5262.11% in 2025.
  • Over the past 5 years, Coherus Oncology's Total Current Liabilities (Quarter) stood at $165.3 million in 2021, then decreased by 16.11% to $138.7 million in 2022, then surged by 139.21% to $331.8 million in 2023, then dropped by 14.71% to $283.0 million in 2024, then skyrocketed by 31.56% to $372.3 million in 2025.
  • Its Total Current Liabilities stands at $372.3 million for Q3 2025, versus $263.6 million for Q2 2025 and $255.0 million for Q1 2025.